Complaint Board

 
Beginning Of The Month Received During The Month Resolved During the month Pending At The End Of The Month Reasons for Pendency
0 0 0 0 0
 

*Please Note: The amount that you are paying in the company is purely the fees of our services and not Investment. Investment is to be done by your side and in your DEMAT account only.

Complaint Board

 
Beginning Of The Month Received During The Month Resolved During the month Pending At The End Of The Month Reasons for Pendency
0 0 0 0 0
 

*Please Note: The amount that you are paying in the company is purely the fees of our services and not Investment. Investment is to be done by your side and in your DEMAT account only.

Buy Aurobindo Pharma; Target of Rs 1027: Trade Nivesh

Trade Nivesh | is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1027 in its research report dated August 17, 2020.

Aurobindo reported Revenue growth of 8.8% YoY (-3.8% QoQ) to INR 59.2 bn, led by the US, & Antiretroviral business. Formulation business grew 9.2% YoY( -4.8% QoQ, ~87% of revenue) while API rose 6.5% YoY (+3.2% QoQ, ~13% of revenue). EBITDA for the quarter rose 9.7% YoY (-4.5% QoQ) to INR 12.6 bn while EBITDA margin expanded 17 bps YoY/ (down 15 bps QoQ) to 21.2% in 1QFY21 (from 21.1% last year). Adj Net Profit rose 20.4% YoY (-6.8% QoQ) to INR 7.8 bn. Adj. Net Profit Margin for the quarter expanded 126 bps YoY to 13.2.0% (down 43 bps QoQ) from 11.9% in 1QFY20. Reported PAT came at INR 7,806 mn (+22.8% YoY, -8.1% QoQ). Investment in Research for the quarter was INR 2.5 bn at 4.3% of revenue. Net organic capex for the quarter was ~USD 49 million. Aurobindo received final approval for 10 ANDAs from USFDA during the quarter. Company announced an interim dividend of INR 1.25/share for FY20-21. get the short term or on medium term

Outlook

In the wake of in-line performance in 1QFY21, faster than expected debt reduction/stable margins & nearing of regulatory clearance, we raise our target price upwards to INR 1,027/share (earlier INR 894/share) by applying a higher PE multiple of 15.5x on FY22E EPS of INR 66.3/share (earlier P/E multiple 13.5x ), an upside potential of 17.0%. Accordingly, we reiterate a “BUY” rating on the shares of Aurobindo Pharma.

Read More
admin August 19, 2020 0 Comments
TEST US TRADER

 

An initiative by Trade Nivesh in interest of all Investors and Traders .

Beware about the Fraudulent activity by the name of Trade Nivesh. Please do not make any payment except bank account details mentioned on our website in order to avoid any financial harm.

In-case of such activity, kindly do inform us at +91-731-3517084 /+91-90390-02130 or mail us at compliance@tradenivesh.com.